Agios (AGIO) Files $86M IPO
Tweet
Share
E-mail
Get Alerts AGIO Hot Sheet
Join SI Premium – FREE
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $86 million.
The offering is being made through J.P. Morgan, Goldman, Sachs & Co., Cowen and Company, and Leerink Swann.
Agios Pharma a biopharmaceutical company passionately committed to applying its scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and inborn errors of metabolism, or IEMs, which are a subset of orphan genetic metabolic diseases.
The offering is being made through J.P. Morgan, Goldman, Sachs & Co., Cowen and Company, and Leerink Swann.
Agios Pharma a biopharmaceutical company passionately committed to applying its scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and inborn errors of metabolism, or IEMs, which are a subset of orphan genetic metabolic diseases.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Shake Shack (SHAK) Announces Resignation of Jonathan Sokoloff from Board, Cuts Board Size to 10 from 11
- Lithium Americas Corp (LAC) Announces Proposed 55M Share Offering
- Trump Media & Technology (DJT) Declines 17% on Concerns Stockholders May Sell Shares
Create E-mail Alert Related Categories
IPOsRelated Entities
JPMorgan, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
